Contribute Try STAT+ Today

Good morning, everyone, and how are you today? As the saying goes, stay on the sunny side. So despite the doom and gloom, our cup of stimulation is half full. Of course, it helps that our new official mascot is a playful and amusing distraction. Nonetheless, there is work to be done. So time to get cracking. As always, we have assembled a few items of interest to help you along. We hope today is productive and manageable. Best of luck. Stay safe and stay in touch.

India will allow limited exports of hydroxychloroquine after President Trump warned the country may face retaliation if it did not withdraw the ban on exports, Reuters reports. Trump has touted the drug as a potential weapon in the fight against Covid-19, despite a lack of evidence that it works and a subsequent debate inside his administration. The Indian government had put a hold on exports over concerns that stocks were depleting because of the hit to global supply chains after the novel coronavirus emerged in China late last year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.